Koffiekamer « Terug naar discussie overzicht

Swingtrades in reguliere bedrijven

5.451 Posts, Pagina: « 1 2 3 4 5 6 ... 98 99 100 101 102 103 104 105 106 107 108 ... 269 270 271 272 273 » | Laatste
[verwijderd]
0
quote:

crackedtooth schreef op 10 februari 2012 16:24:

TVIX meeste eruit 18.20 restant

dat is meer dan +28% binnen drie dagen
vandaag onder de 16.50
was dus een goede trade
nog niet teruggekocht hier
[verwijderd]
0
[verwijderd]
0
quote:

crackedtooth schreef op 14 februari 2012 21:49:

PWAV alsnog entry 1.55
wel voor earnings, wat normaal niet verstandig is
wat dus ook blijkt
drulletje drie
0
quote:

crackedtooth schreef op 15 februari 2012 16:04:

[...]
wat dus ook blijkt
oei wel hele slechte resulaten....
wat is je taktiek nu?
[verwijderd]
0
drulletje, eruit met verlies

verlies pakken TENZIJ er een binary event komt
daarna chart loeren en bij nieuwe setup kun je ALTIJD tergkopen

niets is zo slecht om in een positie te blijven wanneer een trenlijn is gebroken

was een kleine positie, dus niet leuk maar zeker niet erg
hoort erbij, verliezen
als je meer winst dan verliest dat is de truc
drulletje drie
0
Inderdaad crack klopt! Was benieuwd hoe je dit geen "spelen".
Je zou ook kunnen middelen maar je pakt "gewoon" je verlies.
[verwijderd]
0
quote:

drulletje drie schreef op 15 februari 2012 16:48:

Inderdaad crack klopt! Was benieuwd hoe je dit geen "spelen".
Je zou ook kunnen middelen maar je pakt "gewoon" je verlies.

NOOIT zomaar middelen of "bijkopen"
iedere aankoop altijd als een nieuwe positie bekijken

wanneer soms wel bijkopen of langzaam accumuleren->richting binary events zoals bv fda rulings (maar dan kan je door verwatering weer verrast worden of bv slechte trial data) en soms ook bij low volume stocks
drulletje drie
0
Nog even de dead cat bounce afgewacht ;)
Scheelt toch weer een paar cent.

En waarschijnlijk heb je de volgende alweer op het oog jou kennende
[verwijderd]
0
IBIO lees de 10Q , mede waarom ik hem langzaam aan kopen ben, cost avg onder .80

IBIO background overview as filed in 10Q

biz.yahoo.com/e/120214/ibio10-q.html

iBio, Inc. ("iBio" and the "Company") is a biotechnology company focused on commercializing its proprietary technology, the iBioLaunch? platform, for biologics including vaccines and therapeutic proteins. Our strategy is to promote our technology through commercial product collaborations and license arrangements. We expect to share in the increased value our technology provides through upfront license fees, milestone revenues, service revenues, and royalties on end products. We believe our technology offers the opportunity to develop products that might not otherwise be commercially feasible, and to work with both corporate and government clients to reduce their costs during product development and meet their needs for low-cost, high-quality biologics manufacturing systems. Our near-term focus is to establish business arrangements for use of our technology by licensees for the development and production of products for both therapeutic and vaccine uses.

Vaccine candidates presently being advanced on our proprietary platform are applicable to newly emerging strains of H1N1 swine-like influenza, and H5N1 avian influenza, yellow fever, malaria, and anthrax. Therapeutic candidates presently being advanced on our proprietary platform include human alpha-galactosidase A for the treatment of Fabry disease, human C1 esterase inhibitor for the treatment of hereditary angioedema (HAE), human alpha-1 antitrypsin for treatment of disorders caused by a lack or deficiency of alpha-1 antitrypsin, a therapeutic vaccine for human papilloma virus (HPV), and several other therapeutic protein targets for which preliminary product feasibility has been demonstrated.

In order to attract appropriate licensees and increase the value of our share of such intended contractual arrangements, we engaged the Center for Molecular Biotechnology of Fraunhofer USA, Inc., or FhCMB, in 2003 to perform research and development activities to develop the platform and to create our first product candidate. We selected a plant-based influenza vaccine for human use as the product candidate to exemplify the value of the platform. Based on research conducted by FhCMB, our proprietary technology is applicable to the production of vaccines for any strain of influenza of H1N1 swine-like influenza. A Phase 1 clinical trial of a vaccine candidate for H1N1 influenza, based on iBio's technology, was initiated in September 2010. We announced positive interim results in June 2011. The vaccine candidate demonstrated strong induction of dose correlated immune responses, with or without adjuvant, as assessed by virus microneutralization antibody assays and hemagglutination inhibition ("HAI") responses. The vaccine was safe and well tolerated at all doses when administered with and without adjuvant.

In connection with the research and development agreement, FhCMB agreed to use its best efforts to obtain grants from governmental and non-governmental entities to fund additional development of our proprietary plant-based technology. Consequently, in addition to the funding we have provided, FhCMB has received funding from the Bill & Melinda Gates Foundation for development of various vaccines based upon our proprietary technology including an experimental vaccine for H5N1 avian influenza. A Phase 1 clinical trial of a vaccine candidate for H5N1 influenza, based on iBio's technology, was initiated in December 2010 and is ongoing. The results of this trial are expected to be released during the first half of calendar year 2012.

In addition to the platform and product development engagements, in 2006, the Company engaged FhCMB to create a prototype production module for products made through the use of the platform. The purpose of this engagement was to demonstrate the ease and economy with which platform-based products could be manufactured in order to attract potential licensees and increase the value of our share of such business arrangements. The prototype design, which

drulletje drie
0
quote:

crackedtooth schreef op 6 februari 2012 18:24:

Superconductor Technologies Inc. Signs a Product Development Agreement With a Global Leader in Mobile Communications Products

Leverages IP Portfolio to Incubate Technology Separate From Main 2G HTS Wire Business

AUSTIN, Texas, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Superconductor Technologies Inc. (Nasdaq:SCON - News) ("STI"), a world leader in the development and production of high temperature superconducting (HTS) materials and associated technologies, signed a product development agreement with a global market leader to develop its innovative Reconfigurable Resonance(TM) (RcR) technology in the rapidly growing mobile communications products industry.

Jeff Quiram, STI's president and chief executive officer said, "While our main focus continues to be 2G HTS wire, STI has long sought to exploit other parts of its intellectual property portfolio where opportunities present themselves. This agreement is the result of these ongoing efforts. Our RcR technology shows exciting promise and this agreement is an important validation of our strategy."

The planned development project intends to advance STI's proprietary RcR technology from innovation to commercialization. STI developed this novel technology by extending its world-leading expertise in analog passive circuit design into the arena of active analog circuitry. This research effort has produced an entirely new circuit design methodology, which has the potential to be broadly applicable to many of the critical challenges facing analog circuit design today.

STI's newly formed subsidiary, Resonant Inc., entered the product development agreement, and will have responsibility for the development effort. Resonant will require financing in order to commence active development, and STI is currently exploring financing options. While there is no assurance as to whether Resonant will obtain the necessary financing, STI expects to transfer the RcR technology and related personnel to Resonant when such financing is obtained. The creation of this new entity positions STI to advance one of several innovative technologies that are distinctly separate from the Company's primary focus on HTS wire development.

The development agreement includes quarterly milestones with a project scope that involves development and qualification testing of new mobile communications products using STI's RcR technology for sales into an existing multi-billion dollar mobile communications market.

finance.yahoo.com/news/Superconductor...
[verwijderd]
0
Eentje om in de gaten te houden: COMV

Had al een kleine positie, gisteren ging die even van start. Heb vandaag in de low's bijgekocht. Grtz
[verwijderd]
0
quote:

Eisbear schreef op 1 maart 2012 17:38:

Eentje om in de gaten te houden: COMV

Had al een kleine positie, gisteren ging die even van start. Heb vandaag in de low's bijgekocht. Grtz
op chart? of komen er nieuws events?
[verwijderd]
0
Hi Crack, vooral op vooruitzichten, maar ook deels op chart (vooral korte termijn)
5.451 Posts, Pagina: « 1 2 3 4 5 6 ... 98 99 100 101 102 103 104 105 106 107 108 ... 269 270 271 272 273 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
931,68  +1,90  +0,20%  11:00
 Germany40^ 22.673,30 +1,17%
 BEL 20 4.453,01 +1,23%
 Europe50^ 5.505,24 +1,05%
 US30^ 43.741,00 +0,29%
 Nasd100^ 21.248,60 +0,76%
 US500^ 5.984,70 +0,49%
 Japan225^ 38.213,90 +0,65%
 Gold spot 2.913,26 -0,11%
 EUR/USD 1,0497 -0,16%
 WTI 68,93 -0,17%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

JDE PEET'S +6,23%
RANDSTAD NV +4,96%
Accsys +4,54%
AMG Critical ... +4,49%
ArcelorMittal +4,45%

Dalers

Wolters Kluwer -7,72%
EBUSCO HOLDING -3,46%
AZERION -0,86%
ASMI -0,84%
RELX -0,81%